|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
2/2013
vol. 12 abstract:
Review paper
New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy
Krzysztof Gałczyński
,
Ewa Poleszak
,
Regina Kasperek
,
Katarzyna Romanek-Piva
,
Beata Kulik-Rechberger
,
Tomasz Rechberger
Przegląd Menopauzalny 2013; 2: 111–114
Online publish date: 2013/05/13
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
According to novel theory menopausal symptoms are not only connected with estrogen deficiency due to diminished ovarian estrogen secretion, but are also associated with the gradual, progressive decline in the level of dehydroepiandrosterone (DHEA) secreted by the adrenal glands. Over 50% of postmenopausal women report symptoms associated with urogenital atrophy, ie: irritation, recurrent infections, dryness, dyspareunia. Systemic hormonal therapy with estrogens or in combination with progestins is an effective treatment of these symptoms, however, it is associated with some adverse effects. In addition, it is worthwhile to think about local therapy in case of women who have only symptoms associated with urogenital atrophy. Promising are results of the studies of DHEA intravaginal therapy, in which it was assumed that physiological doses of DHEA contribute to an increase in androgens and estrogens synthesized locally in tissues by intracrine mechanisms with low systemic effects. Previous studies have shown that intravaginal DHEA application reduce the symptoms of vaginal atrophy, regress low-grade cervical dysplasia and increase libido.
keywords:
dehydroepiandrosterone, urogenital atrophy, menopause |
 |
